Bio

Paul Parren is an internationally recognized antibody drug innovator and developer. Paul was Head of Preclinical Development and Research at Genmab (2002-2017), translating antibody biology successfully into immunotherapies from discovery to the clinic, including approved therapeutic antibodies ofatumumab and daratumumab, as well as establishing validated antibody platform technologies. He is a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden, the Netherlands, board member of The Antibody Society and was an Associate Professor at The Scripps Research Institute in La Jolla, California. He holds a PhD in Molecular Immunology from the University of Amsterdam. Paul assists Gilde in the evaluation of investment opportunities and is also acting as Executive Vice President and Head of Research & Development for Gilde’s portfolio company Lava Therapeutics.